![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Severens Johan L.
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.26, Iss.11, 2008-01, pp. : 899-900
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Loss Aversion and Cost Effectiveness of Healthcare Programmes
PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Considering loss aversion in economic evaluations
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 565, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cost effectiveness of adjuvant chemotherapy a generation game?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 634, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cost effectiveness of risperidone: is compliance the key?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 614, 2010-01 ,pp. :